Archive for the 'Pleural' Category
Malignant pleural mesothelioma; mesothelioma of the lining of the lungs, or pleura.
January 26th, 2011. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma
Conclusions: The determination of histological subtype from a diagnostic biopsy is difficult due to sampling error, but an adequate specimen obtained from surgical biopsy increases the accuracy of subtype classification compared with radiological-guided biopsies.
Posted in Biphasic or Mixed, CT or CAT scan, Diagnosis & Differentiation, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Surgery, thoracoscopy, thoracotomy, Type of Assessment:, Type of Mesothelioma: | 3 Comments »
January 26th, 2011. Targeted therapies in malignant pleural mesothelioma: a review of clinical studies
However, none of these has yet reached daily practice. That is the reason why efforts must continue in the area of clinical and translational research for MPM.
January 25th, 2011. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin
Conclusions: In our series of carboplatin-/pemetrexed-treated MPM patients, low TS protein and mRNA levels were significantly associated to DC, improved PFS, and OS. Prospective trials for the validation of the prognostic/predictive role of TS in MPM patients treated with pemetrexed-based regimens are warranted.
January 25th, 2011. Thoracoscopic extrapleural pneumonectomy for mesothelioma
Surgical therapy offers limited cure benefits at the cost of high morbidity. Although technically challenging and performed rarely, a less invasive approach to extrapleural pneumonectomy was developed with the intent to speed convalescence, hasten adjuvant therapies, improve quality of life, and reduce wound surface area for possible tumor contamination.
January 19th, 2011. Biological Materials for Diaphragmatic Repair: Initial Experiences with the PeriGuard Repair Patch®
Conclusion: We consider the PeriGuard Repair Patch® a viable alternative to synthetic materials for diaphragm replacement. Moreover, we advise carrying out cautious follow-up in patients undergoing extensive oncological resection to learn more about the biological behavior of the bovine PeriGuard Repair Patch® after diaphragmatic repair.
January 15th, 2011. Validation of tissue microarray technology in malignant pleural mesothelioma
Conclusion: If a minimum of four cores is used, TMA is an appropriate method for immunohistochemistry in MPM.
January 14th, 2011. Dasatinib: An Anti-Tumour Agent via Src Inhibition
The most common non-haematologic adverse events include gastrointestinal symptoms (diarrhoea, nausea, vomiting, abdominal pain and anorexia), headache, peripheral edema, and pleural effusion. In respect of these encouraging studies investigating dasatinib in the treatment of patients with GIST, prostate cancer, multiple myeloma and sarcomas, ongoing phase III clinical trials warrant the drug evaluation as recommended agent for the treatment of these diseases, also in association with chemoterapy or other targeted therapies.
January 14th, 2011. mesothelioma cell proliferation requires p38δ mitogen activated protein kinase and C/EBP-α
Furthermore, TGF-β inhibited PDGF-BB induced proliferation by interruption of p38 MAPK signalling. From this rat model, we conclude that in pleural mesothelioma, p38δ in C/EBP-α mediate proliferation and thus may represent new targets in mesothelioma therapy.
January 12th, 2011. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
In conclusion, re-treatment with PBC should be considered as second-line therapy in MPM patients achieving a durable (>12 months) disease control with first-line PBC. Further prospective evaluation of this therapeutic option is warranted.
January 8th, 2011. The pleura in health and disease
, laterality) is often of great value to the pathologist in arriving at a correct diagnosis. Similarly, knowledge of the normal anatomical considerations and familiarity with the expected pleural histopathology for the most clinically relevant pleural diseases are critical assets for pulmonary physicians in providing optimal care for their patients.
January 7th, 2011. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival
Conclusion: FDG PET/CT is an accurate modality to diagnose and to estimate the extent of locoregional and distant MPM recurrence, and it carries independent prognostic value. Once the disease recurs, survival outcomes seem to be independent of histologic type and highly dependent on the intensity of lesion uptake and on the pattern of metabolically active disease in FDG PET/CT. Our observations should be considered limited to patients treated surgically with or without perioperative therapies and should not be extrapolated to those unresectable cases treated with chemotherapy alone. Keywords FDG, FDG PET/CT, Mesothelioma, Lung cancer, Response to treatment, Recurrence, Survival
January 6th, 2011. Establishment of a cell line from Japanese patient useful to generate an in vivo model for malignant pleural mesothelioma
These results indicate that MM56 cells can behave in a manner characteristic of human malignant pleural mesothelioma in the thoracic cavity of BALB/c-nude mice. The in vivo model using MM56 cells may be useful to study the biological behavior of malignant pleural mesothelioma and develop its diagnostic and therapeutic strategies.
January 5th, 2011. Antiangiogenic therapies for malignant pleural mesothelioma
Further understanding of the functional characteristics of tumor angiogenesis may be essential to improve targeting therapies in MPM. In this review, we introduce current status of clinical strategies and novel therapeutic approaches against angiogenesis in MPM.
January 6th, 2009. The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas
0004). Our study indicated that BMP3b and BMP6 genes were suppressed by DNA methylation and methylation of BMP3b is significantly frequent in Japanese MPMs, suggesting its pathogenic role and the ethnic difference in MPMs.
January 2nd, 2009. Epigenetic Profiles Distinguish Pleural Mesothelioma from Normal Pleura and Predict Lung Asbestos Burden and Clinical Outcome
We have added to the growing body of evidence that cellular epigenetic dysregulation is a critical mode of action for asbestos in the induction of pleural mesothelioma. Importantly, these findings hold great promise for using epigenetic profiling in the diagnosis and prognosis of human cancers.
January 2nd, 2009. A new electrocautery pleural biopsy technique using an insulated-tip diathermic knife during semirigid pleuroscopy
Conclusions: Electrocautery biopsy using the IT knife during semirigid pleuroscopy has great potential for diagnosing smooth abnormal pleura which are difficult to biopsy with SFF.
December 23rd, 2008. Malignant mesothelioma
Compensation issues must also be considered. Life expectancy in malignant mesothelioma is poor, with a median survival of about one year following diagnosis.
Posted in Benign, Causation, CT or CAT scan, Diagnosis & Differentiation, Environmental Asbestos Exposure, Full Archive, General, Occupational Asbestos Exposure, Pericardial, Peritoneal (Abdominal Mesothelioma), Pleural, Survival, Symptoms & Symptom Management, Treatment, Trimodality Therapy, Tunica Vaginalis Testis, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 20th, 2008. Vitamin D-mediated hypercalcemia and Cushing syndrome as manifestations of malignant pleural mesothelioma
Conclusion: These findings support the evidence for a paracrine role of vitamin D in the resistance of the human host to antigen.
December 19th, 2008. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
Conclusion: Pemetrexed-pretreated patients with progressive MPM may benefit from a consecutive chemotherapy with oxaliplatin and gemcitabine without significant toxicity.
December 17th, 2008. An autopsy case of sarcomatoid malignant mesothelioma mimicking adenocarcinoma with sarcomatoid elements of lung
Therefore, immunohistochemical staining was performed; the findings revealed sarcomatoid malignant mesothelioma. In conclusion, we encountered a rare case of sarcomatoid malignant mesothelioma (stage IV).
|
|  |
